InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. (INM): 4 pipeline candidates · ~10 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
10.1 months
D/E 0.33 · 22% dilution
Lead: Phase 2
4 candidates
N/A
21 buys · 0 sells (180d)
A transparent, data-derived signal for InMed Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.9M
Cash
$5.2M
Quarterly Burn
$1.7M
Runway
10.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in InMed Pharmaceuticals Inc.'s pipeline?
InMed Pharmaceuticals Inc. (INM) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is InMed Pharmaceuticals Inc.'s lead drug candidate?
InMed Pharmaceuticals Inc.'s most advanced tracked candidate is inm-088 (Preclinical) for glaucoma.
What is InMed Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, InMed Pharmaceuticals Inc. has approximately 10.1 months of cash runway.
What is InMed Pharmaceuticals Inc.'s market capitalization?
InMed Pharmaceuticals Inc.'s market capitalization is approximately $4.9M.
Who is the CEO of InMed Pharmaceuticals Inc.?
Mr. Eric A. Adams B.S. Chem., M.I.B. is the chief executive officer of InMed Pharmaceuticals Inc. (INM).
Get the full picture on InMed Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.